PRMT3 and neoplasm: Checkpoint inhibitor therapy stimulates CD8+ T cell activation, thus inducing ferroptosis in tumors to exert antitumor effects.[21, 47] Our work showed that PRMT3 depletion accelerated ferroptosis in tumor cells by regulating METTL14 expression.